Virchows Archiv

, Volume 453, Issue 2, pp 133–139

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

  • Enrique Lerma
  • Lluis Catasus
  • Alberto Gallardo
  • Gloria Peiro
  • Carmen Alonso
  • Ignacio Aranda
  • Agusti Barnadas
  • Jaime Prat
Original Article

DOI: 10.1007/s00428-008-0643-4

Cite this article as:
Lerma, E., Catasus, L., Gallardo, A. et al. Virchows Arch (2008) 453: 133. doi:10.1007/s00428-008-0643-4

Abstract

PIK3CA mutations at 9 and 20 exons were studied in a series of 56 selected aggressive breast carcinomas (BC): 27 with Her-2 over-expression and negativity for estrogen receptors (ER) and progesterone receptors (PR), and 29 “triple negative” BC (negative for ER, PR and Her-2). Also, immunohistochemical studies of p53, ki-67, Her-1 (EGFR), pIGF-1R, PTEN, p110α, and pAkt were performed. Six mutations in exon 20 PIK3CA were identified among the 27 Her-2 positive BC, whereas only one exon 9 PIK3CA mutation was detected in a triple negative tumor (p = 0.035). Furthermore, PIK3CA mutations were associated with p110α over-expression (p = 0.001). Overall survival was shorter in cases with PIK3CA mutations (p = 0.015 in all series; and p = 0.041 for Her-2+ tumors), although multivariate analyses did not show statistical differences. No statistical significance was related with disease-free survival. Exon 20 PIK3CA mutations are relatively frequent in Her-2+ tumors and shorten survival, whereas neither exons 9 and 20 mutations seem related with “triple negative” breast carcinomas.

Keywords

Breast carcinomaHer2-neup110PIK3CA mutations

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Enrique Lerma
    • 1
    • 4
  • Lluis Catasus
    • 1
  • Alberto Gallardo
    • 1
  • Gloria Peiro
    • 3
  • Carmen Alonso
    • 2
  • Ignacio Aranda
    • 3
  • Agusti Barnadas
    • 2
  • Jaime Prat
    • 1
  1. 1.Department of Pathology, Hospital de la Santa Creu i Sant PauAutonomous University of BarcelonaBarcelonaSpain
  2. 2.Department of OncologyHospital de la Santa Creu i Sant PauBarcelonaSpain
  3. 3.Department of PathologyHospital General UniversitarioAlicanteSpain
  4. 4.Department of PathologyHospital de la Santa Creu i Sant PauBarcelonaSpain